donor-derived CD7 CAR T-cell / Beijing GoBroad Hospital - LARVOL DELTA

Five year follow-up of donor-derived CD7 CAR T-cell therapy for r/r T-cell acute lymphoblastic leukemia (ASH 2025) - "After a median follow-up time of 56.2(range, 32.1-60.6) months.Six patients (33.3%) had a relapse(four CD7-negative, and two CD7-positive), is the same as the result of the 2-year follow-up. 5-year PFSrate and OS rate were 24.5% (95% CI, 3.9-45.8%) and 24.1% (95% CI, 3.5-44.7%), respectively , and themedian PFS and OS were 11.0 (range, 7.3-14.6) months and 18.2 (range, 10.8-25.6) months, respectively.For patients without SCT, 5-year PFS and OS rates were 10.6% respectively, and the median PFS and OSwere 11.0 (range, 7.8-14.2) months and 18.3 (range, 6.9-31.8) months, respectively. For patients with SCT,5-year PFS and OS rates were 42.9% respectively."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Novel Coronavirus Disease • Otorhinolaryngology • Pneumonia • Respiratory Diseases • Sinusitis • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • CD34 • CD7

CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study (ASH 2025) - P=N/A | "Background : The prognosis of refractory/relapsed T-cell lymphoma is extremely poor, especially for thepatients who failed to allogeneic hematopoietic stem cell transplantation(alloHSCT).Aims: In this single-center Phase I study (ChiCTR2200058969), we administered CD7 CAR T cells toevaluate extended safety, PK, tolerability and efficacy in patients with r/r T-cell lymphoma.CD7 CAR T-cells is a product in which collected mononuclear cells have been transduced with thelentiviral vector carrying a CD7 CAR construct binding domain fused to a domain for anchoring in theendoplasmic reticulum, allowing CD7 to be retained intracellularly, thereby preventing CAR T cellfraticide.CD7 CAR T-cells was evaluated in a phase Ia study with a 3+3 dose-escalation design followed by cohortexpansion.The phase Ia study is being conducted with different dose levels (DL): 1×104 (DL1), 5×104 (DL2),1×105 (DL3) (±30%) CAR+ cells/kg.Data from phase Ia trial will be used..."

CAR T-Cell Therapy • Clinical • P1 data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cutaneous T-cell Lymphoma • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Natural Killer/T-cell Lymphoma • Neutropenia • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • CD7

CD7 CAR T-Cell Therapy in Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia: A Retrospective Study (ASH 2024) - P=N/A, P2 | "Method This is a retrospective analysis of donor-derived CD7 CAR T-cell therapy in r/r T-ALL, based on a phase 1 trial (ChiCTR2000034762) and a phase 2 trial (NCT04689659)...Conclusion These data demonstrated that non-CNS EMD and bone marrow burden were independent risk factors for inferior survival in patients who received donor-derived CD7 CAR T therapy. SCT consolidation may exert a beneficial impact on them."

CAR T-Cell Therapy • Retrospective data • Acute Lymphocytic Leukemia • Central Nervous System Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • CD7

Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL: a phase 2 trial. (PubMed, Blood) - P2 | "While effective at inducing remission, death in remission beyond 30 days is a concern. NCT04689659."

Journal • P2 data • Acute Lymphocytic Leukemia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Liver Failure • Lymphoma • Oncology • Pediatrics • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • Transplantation • CD7

AUTOLOGOUS AND DONOR-DERIVED CD7-KNOCKOUT CD7-TARGETED CAR T THERAPY IN RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE 1/2 CLINICAL STUDY (EHA 2025) - P1/2 | "For patients without SCT history, if the patient had peripheral tumor burden ≤20% and lymphocytes >0.5×109/L, autologous PBMCs would be preferred; otherwise, PBMCs from a newly HLA-matched donor would be collected.From March 2024 to December 2024, 34 patients were enrolled, including 18 who received autologous CD7 CAR T cells (cohort A), seven who received prior SCT donor-derived CD7 CAR T cells (cohort B), and nine who received newly HLA-matched donor-derived CD7 CAR T cells (cohort C). Patients had comparable response rates to different sources of CD7 CAR T cells. The relatively rapid recovery from severe cytopenias after autologous therapy may underlie a better long-term safety profile. However, the risk of infection after CAR T therapy derived from prior-SCT donor warrants further attention."

Clinical • P1/2 data • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • CD7

EFFICACY AND TOXICITY OF DONOR-DERIVED CHIMERIC CD7 ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH T-CELL LYMPHOMA WHO RELAPSE AFTER ALLOGENEIC TRANSPLANTATION (EBMT 2025) - P=N/A | "Our study demonstrates that donor-derived CD7 CAR T-cell therapy is highly effective for patients with T-cell lymphoma who relapse after allogeneic transplantation. However, the substantial risk of infections and subsequent relapses in later stages significantly impacts survival rates. Therefore, further research into effective options is essential."

Clinical • IO biomarker • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatosplenic T-cell Lymphoma • Immunology • Infectious Disease • Leukemia • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • T Cell Non-Hodgkin Lymphoma • Transplantation • CD7